File Download
 
 
Supplementary

Conference Paper: Interim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infection.
  • Basic View
  • Metadata View
  • XML View
TitleInterim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infection.
 
AuthorsYuen, RMF
Kim, J
Wong, DKH
Ngai, WS
Yuen, JCH
Lai, CL
 
Issue Date2004
 
Citation39th Annual Meeting of the European Association for the Study of Liver, Berlin, Germany 14-18 Apr 2004 (published in J Hepatol) , v. 40 n. Suppl 1, p. 114 [How to Cite?]
 
DC FieldValue
dc.contributor.authorYuen, RMF
 
dc.contributor.authorKim, J
 
dc.contributor.authorWong, DKH
 
dc.contributor.authorNgai, WS
 
dc.contributor.authorYuen, JCH
 
dc.contributor.authorLai, CL
 
dc.date.accessioned2010-09-25T20:12:56Z
 
dc.date.available2010-09-25T20:12:56Z
 
dc.date.issued2004
 
dc.identifier.citation39th Annual Meeting of the European Association for the Study of Liver, Berlin, Germany 14-18 Apr 2004 (published in J Hepatol) , v. 40 n. Suppl 1, p. 114 [How to Cite?]
 
dc.identifier.hkuros105373
 
dc.identifier.issueSuppl 1
 
dc.identifier.spage114
 
dc.identifier.urihttp://hdl.handle.net/10722/101997
 
dc.identifier.volume, v. 40 n. Suppl 1
 
dc.languageeng
 
dc.relation.ispartof39th Annual Meeting of the European Association for the Study of Liver, Berlin, Germany 14-18 Apr 2004 (published in J Hepatol)
 
dc.titleInterim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infection.
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yuen, RMF</contributor.author>
<contributor.author>Kim, J</contributor.author>
<contributor.author>Wong, DKH</contributor.author>
<contributor.author>Ngai, WS</contributor.author>
<contributor.author>Yuen, JCH</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<date.accessioned>2010-09-25T20:12:56Z</date.accessioned>
<date.available>2010-09-25T20:12:56Z</date.available>
<date.issued>2004</date.issued>
<identifier.citation>39th Annual Meeting of the European Association for the Study of Liver, Berlin, Germany 14-18 Apr 2004 (published in J Hepatol) , v. 40 n. Suppl 1, p. 114</identifier.citation>
<identifier.uri>http://hdl.handle.net/10722/101997</identifier.uri>
<language>eng</language>
<relation.ispartof>39th Annual Meeting of the European Association for the Study of Liver, Berlin, Germany 14-18 Apr 2004 (published in J Hepatol)</relation.ispartof>
<title>Interim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infection.</title>
<type>Conference_Paper</type>
<identifier.hkuros>105373</identifier.hkuros>
<identifier.volume>, v. 40 n. Suppl 1</identifier.volume>
<identifier.issue>Suppl 1</identifier.issue>
<identifier.spage>114</identifier.spage>
</item>